ReviewWorld journal of urology2026
Contemporary management of locally advanced prostate cancer: a narrative review and expert perspective.
Review in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Article
- Pathological complete response to perioperative treatment with darolutamide plus ADT in locally advanced prostate cancer without PTEN or RB1 loss: a case report.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLocally advanced prostate cancer (PCa) encompasses a heterogeneous group of patients, including those with clinical stage T3–T4 disease and/or regional lymph node involvement (cN1), without distant metastases. While curative-intent treatment remains the goal in many cases, optimal management strategies are still subject to debate due to limited high-level evidence and variability in clinical guidelines.
objectiveThis narrative review summarizes current treatment guidelines, appraises recent clinical evidence, and offers an expert perspective on contemporary management strategies for patients with locally advanced PCa.
methodsA narrative review of international guidelines and recent clinical trials was conducted, focusing on the role of external beam radiotherapy (EBRT), androgen deprivation therapy (ADT), radical prostatectomy (RP), and systemic treatment intensification using androgen receptor pathway inhibitors (ARPIs) and chemotherapy. In addition, we highlight the impact of novel imaging modalities such as PSMA-PET/CT.
resultsThe established standard of care remains EBRT combined with ADT, with the addition of abiraterone now recommended for selected high-risk cases. RP, although not yet supported by randomized trials, may provide oncological and functional benefits in carefully chosen patients and is increasingly being incorporated into multimodal treatment strategies. The role of intensified neoadjuvant or adjuvant systemic therapies, however, remains under investigation.
conclusionCurrent management of locally advanced PCa requires individualized decision-making based on modern imaging modalities, patient characteristics, tumor biology, and available resources. While EBRT based multimodal concepts are mainly the preferred treatment, RP based multimodal concepts play an important role in selected cases. Emerging systemic therapies and advanced imaging may further refine treatment strategies in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.